Healthcare Provider Perspectives on HIV Cure Research in Ghana.

IF 1.1 Q4 INFECTIOUS DISEASES
Helena Lamptey, Benjamin Newcomb, Evelyn Y Bonney, James O Aboagye, Peter Puplampu, Vincent J Ganu, Gloria Ansa, Joseph Oliver-Commey, George B Kyei
{"title":"Healthcare Provider Perspectives on HIV Cure Research in Ghana.","authors":"Helena Lamptey,&nbsp;Benjamin Newcomb,&nbsp;Evelyn Y Bonney,&nbsp;James O Aboagye,&nbsp;Peter Puplampu,&nbsp;Vincent J Ganu,&nbsp;Gloria Ansa,&nbsp;Joseph Oliver-Commey,&nbsp;George B Kyei","doi":"10.1155/2023/8158439","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Antiretroviral therapy (ART) has reduced mortality and improved life expectancy among HIV patients but does not provide a cure. Patients must remain on lifelong medications and deal with drug resistance and side effects. This underscores the need for HIV cure research. However, participation in HIV cure research has risks without guaranteed benefits. We determined what HIV healthcare providers know about HIV cure research trials, the risks involved, and what kind of cure interventions they are likely to recommend for their patients.</p><p><strong>Methods: </strong>We conducted in-depth qualitative interviews with 39 HIV care providers consisting of 12 physicians, 8 counsellors, 14 nurses, 2 pharmacists, 2 laboratory scientists, and 1 community advocate from three hospitals. Interviews were transcribed verbatim and coded, and thematic analysis was performed independently by two investigators.</p><p><strong>Results: </strong>Participants were happy about the success of current treatments and hopeful that an HIV cure will be found in the near future, just as ART was discovered through research. They described cure as total eradication of the virus from the body and inability to test positive for HIV or transmit the virus. In terms of risk tolerance, respondents would recommend to their patients' studies with mild to moderate risks like what patients on antiretroviral therapy experience. Participants were reluctant to recommend treatment interruption to patients as part of a cure study and wished trials could be performed without stopping treatment. Healthcare providers categorically rejected death or permanent disability as an acceptable risk. The possibility of finding a cure that will benefit the individual or future generations was strong motivations for providers to recommend cure trials to their patients, as was transparency and adequate information on proposed trials. Overall, the participants were not actively seeking knowledge on cure research and lacked information on the various cure modalities under investigation.</p><p><strong>Conclusion: </strong>While hopeful for an HIV cure, healthcare providers in Ghana expect a cure to be definitive and pose minimal risk to their patients.</p>","PeriodicalId":46303,"journal":{"name":"AIDS Research and Treatment","volume":"2023 ","pages":"8158439"},"PeriodicalIF":1.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247315/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS Research and Treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/8158439","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Antiretroviral therapy (ART) has reduced mortality and improved life expectancy among HIV patients but does not provide a cure. Patients must remain on lifelong medications and deal with drug resistance and side effects. This underscores the need for HIV cure research. However, participation in HIV cure research has risks without guaranteed benefits. We determined what HIV healthcare providers know about HIV cure research trials, the risks involved, and what kind of cure interventions they are likely to recommend for their patients.

Methods: We conducted in-depth qualitative interviews with 39 HIV care providers consisting of 12 physicians, 8 counsellors, 14 nurses, 2 pharmacists, 2 laboratory scientists, and 1 community advocate from three hospitals. Interviews were transcribed verbatim and coded, and thematic analysis was performed independently by two investigators.

Results: Participants were happy about the success of current treatments and hopeful that an HIV cure will be found in the near future, just as ART was discovered through research. They described cure as total eradication of the virus from the body and inability to test positive for HIV or transmit the virus. In terms of risk tolerance, respondents would recommend to their patients' studies with mild to moderate risks like what patients on antiretroviral therapy experience. Participants were reluctant to recommend treatment interruption to patients as part of a cure study and wished trials could be performed without stopping treatment. Healthcare providers categorically rejected death or permanent disability as an acceptable risk. The possibility of finding a cure that will benefit the individual or future generations was strong motivations for providers to recommend cure trials to their patients, as was transparency and adequate information on proposed trials. Overall, the participants were not actively seeking knowledge on cure research and lacked information on the various cure modalities under investigation.

Conclusion: While hopeful for an HIV cure, healthcare providers in Ghana expect a cure to be definitive and pose minimal risk to their patients.

医疗保健提供者对加纳艾滋病毒治愈研究的看法。
导读:抗逆转录病毒疗法(ART)降低了艾滋病毒患者的死亡率,提高了预期寿命,但不能治愈艾滋病毒。患者必须终生服药,并应对耐药性和副作用。这凸显了艾滋病治愈研究的必要性。然而,参与艾滋病毒治疗研究存在风险,但没有保证的收益。我们确定了艾滋病毒医疗保健提供者对艾滋病毒治愈研究试验的了解程度、涉及的风险以及他们可能向患者推荐的治愈干预措施。方法:对来自3家医院的39名HIV护理人员进行深度定性访谈,其中包括12名医生、8名辅导员、14名护士、2名药剂师、2名实验室科学家和1名社区倡导者。访谈内容逐字记录并编码,专题分析由两名调查人员独立进行。结果:与会者对目前治疗方法的成功感到高兴,并希望在不久的将来能找到治愈艾滋病毒的方法,就像通过研究发现抗逆转录病毒治疗一样。他们将治愈描述为从体内完全根除病毒,并且无法检测出HIV阳性或传播病毒。在风险承受能力方面,受访者会向他们的患者推荐轻度至中度风险的研究,就像抗逆转录病毒治疗患者所经历的那样。参与者不愿意建议患者中断治疗作为治疗研究的一部分,并希望试验可以在不停止治疗的情况下进行。医疗保健提供者断然拒绝将死亡或永久残疾视为可接受的风险。找到一种对个人或后代有益的治疗方法的可能性是提供者向其患者推荐治疗试验的强烈动机,关于拟议试验的透明度和充分信息也是如此。总的来说,参与者没有积极地寻求治疗研究方面的知识,也缺乏关于各种治疗方式的信息。结论:虽然艾滋病毒有望治愈,但加纳的医疗保健提供者希望治愈是决定性的,并对患者构成最小的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
AIDS Research and Treatment
AIDS Research and Treatment INFECTIOUS DISEASES-
CiteScore
3.10
自引率
0.00%
发文量
13
审稿时长
18 weeks
期刊介绍: AIDS Research and Treatment is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies focused on all aspects of HIV and AIDS, from the molecular basis of disease to translational and clinical research. In addition, articles relating to prevention, education, and behavior change will be considered
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信